// App-Quantinova.ai

2122 : Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

Researchers

Presenter

  • Dafna Gladman

Principal Investigators

  • Lars Erik

  • Diamant Thaci

  • Paolo Gisondi

  • Laure Gossec

  • M. Elaine Husni

  • Alice Gottlieb

  • Hiroaki Dobashi

  • Barbara Ink

  • Deepak Assudani

  • Rajan Bajracharya

  • Jason Coarse

  • Jérémy Lambert

  • William Tillett

Medical Centers

  • Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada

  • Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark

  • Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany

  • Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona

  • Sorbonne Universites, Paris, France

  • Cleveland Clinic, Cleveland, OH

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

  • Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, NC, USA, Raleigh, NC

  • UCB Pharma, Colombes, France, Irigny, France

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

Locations

  • Canada

  • Denmark

  • Germany

  • Italy

  • France

  • United States

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03895203

  • NCT03896581

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved